Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years
THOUSAND OAKS, Calif., November 13, 2006 -- Amgen (NASDAQ: AMGN), today announced that data from an ongoing open-label, multinational, phase 4 extension study showed that patients with ankylosing spondylitis (AS) who received treatment with Enbrel? (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy. These...New data reinforce safety profile of ENBREL (etanercept)
Rhodes, Greece, 5 October 2006 -- There was good news for psoriasis patients today as the latest study confirming the established safety profile of ENBREL (etanercept) for up to 2.5 years , was presented at the 15th European Academy of Dermatology and Venereology (EADV) Congress. ENBREL is a biologic, meaning a biotechnologically produced medicine, which acts on one of the root causes of psori...Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
Amsterdam Rheumatoid arthritis patients who are on standard methotrexate therapy may benefit from the addition of the biologic treatment, ENBREL* (etanercept), according to new data from a one-year, open-label extension of the international TEMPO trial. The study results, presented today at the Annual European Congress of Rheumatology, also known as the European League Against Rheumatism (EULA...